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Table. Factors predictive of unplanned readmission after lower extremity
bypass (LEBP)
Predictive factors OR 95% CI P
Predischarge
Urinary tract infection 5.39 1.32-21.97 .019
Surgical site infection 3.73 1.09-12.81 .037
Graft failure 2.51 1.07-5.89 .035
Wound debridement 2.10 1.35-3.27 .001
Transfusion 1.36 1.14-1.62 .001
Dialysis dependence 1.65 1.25-2.17 0
Emergency index surgery 1.41 1.02-1.95 .04
Preoperative foot infection 1.28 1.08-1.51 .004
Body mass index >30 kg/m2 1.25 1.06-1.47 .009
Distal bypass (infrapopliteal target) 1.25 1.06-1.46 .006
Diabetes 1.25 1.06-1.46 .007
Elective index surgery 1.24 1.04-1.48 .015
Bleeding disorder/anticoagulation 1.21 1.02-1.43 .031
Postoperative length of stay 0.98 0.96-0.99 .008
CI, Conﬁdence interval; OR, odds ratio.
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828 Abstracts September 2014methods (bypass 2.9 6 0.9 cm vs stent graft 3.1 6 1.0 cm, P ¼ .5). Pri-
mary patency at 1 and 3 years was 82% and 82% for bypass and 66% and
44% for stent graft, respectively (P ¼ .08). Predictors of loss of primary
patency were stent graft (odds ratio [OR], 6.5; P < .05) and fewer patent
outﬂow vessels (OR, 3.0; P < .05). Secondary patency at 1 and 3 years was
95% and 89% after bypass vs 100% after stent grafting (P ¼ .2; Fig). Hy-
pertension was protective (OR, 0.4; P < .05). No patient required ampu-
tation. Survival at 3 years was similar at 82% after bypass and 89% after
stent grafting (P ¼ .94). Mean length of stay was longer after bypass
(3.6 6 3.8 vs 1.1 6 0.5 days, P < .01).
Conclusions: Although primary patency seems to be worse after stent
graft exclusion of popliteal aneurysms, reinterventions are commonly suc-
cessful and result in an excellent secondary patency rate. Older patients
with limited survival may beneﬁt from stent grafting, whereas patients
with limited outﬂow may beneﬁt from bypass.
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Objective(s): Endovascular revascularization is an established
approach for limb salvage in the setting of critical limb ischemia. However,
failure rate of anterograde recanalization in complex femoropopliteal to
infrapopliteal occlusions is as high as 20%. We report a series of 19 patients
who underwent transpedal access retrograde recanalization of below-the-
knee chronic total occlusions after a failed anterograde attempt.
Methods: Between 2011 and 2014, 19 patients (15 men, 4 women),
aged 68 6 12 years, underwent percutaneous pedal access for retrograde
endovascular treatment of advanced tibial vessel disease. All patients had un-
dergone prior unsuccessful attempts of antegrade revascularization. Pedal
vessel access was followed by angioplasty or stenting, or both, and comple-
tion angiogram. Patients were followed up with duplex ultrasound imaging
to evaluate for patency.
Results: Retrograde pedal access was successful in all patients (dorsalis
pedis, n ¼ 11; posterior tibial, n ¼ 5; anterior tibial, n ¼ 3). Retrograde
revascularization was achieved in 12 patients (63%) using balloon angio-
plasty (n ¼ 12) and balloon angioplasty with stent placement (n ¼ 1).
Revascularization failed in seven patients (37%). Vessels revascularized
included the posterior tibial (n ¼ 3), anterior tibial (n ¼ 3), dorsalis pedis
(n ¼ 8), and the popliteal artery (n ¼ 3). Duplex ultrasound imaging at 2
and 6 months postoperative showed vessel patency. There were no in hos-
pital adverse events.
Conclusions: Pedal vessel access for retrograde angioplasty with or
without stent placement is a feasible option and enhances endovascular op-
tions for revascularization in complex below-the-knee vessel disease with
good results.
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Objectives: Readmission after lower extremity bypass (LEBP) is com-
mon, yet the indication for readmission and its relationship to reoperation
has not been well described. We used the newly available National Surgical
Quality Improvement Project (NSQIP) parameters to evaluate unplanned
readmission #30 days of LEBP.
Methods: All patients undergoing LEBP in the 2012 NSQIP were
identiﬁed. Indications for 30-day reoperation and readmission were identi-
ﬁed. Independent predictors of readmission were determined using logistic
regression. Unplanned readmission was deﬁned as a readmission not
planned at time of index procedure.
Results: We identiﬁed 5375 cases. A total of 858 (16%) underwent
readmission, and 821 (15%) were unplanned readmissions. Incisional surgi-
cal site infection (SSI) was the most common indication for readmission
(36%), followed by wound disruption (13%), and non-SSI wound-related>Eastern Vascular Society
yNew England Society for Vascular Surgerycomplications (14%), including cellulitis (5%), gangrene/tissue loss (5%),
hematoma (3%), and seroma (2%). On multivariable analysis (Table), predis-
charge urinary tract infection was the most signiﬁcant predictor of un-
planned readmission (odds ratio [OR], 5.4) followed by predischarge SSI
(OR, 3.7), graft failure (OR, 2.5), and wound debridement (OR, 2.1).
Amputation before discharge was not predictive of readmission (OR, 1.1;
95% conﬁdence interval, 0.7-1.6). Among patients who were readmitted,
106 (13%) underwent amputation, with 55 (7%) minor (toe or partial
foot), and 51 (6%) major (above-knee or below-knee). A total of 536 pa-
tients underwent predischarge reoperations (65%), most commonly for graft
revision (31%), wound debridement (21%), and amputation (minor, 21%;
major, 12%). A total of 413 patients underwent postdischarge reoperations
(50%), most commonly for wound debridement (38%), graft revision (23%),
and amputation (minor, 13%; major, 12%; Table).
Conclusions: This is the ﬁrst review of data on LEBP patients from a
national database that includes information on the indication for readmis-
sion and speciﬁc reoperation. Although wound debridement is predictive
of unplanned readmission, amputation is not. The prior iterations of NSQIP
have underestimated the number of wound-related complications leading to
readmission. These data may suggest a role for increased outpatient wound
surveillance and early outpatient intervention for wound-related complica-
tions, when possible, to prevent the need for unplanned readmission.
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Objectives: Treatment of chronic venous ulcers (CVU) is difﬁcult and
resource-intensive, with reported healing rates of 20% to 50% with local
wound care and compression. Human viable wound matrix (HVWM) con-
tains extracellular matrix, growth factors, and several viable cells, including
mesenchymal stem cells. In this study, we compared healing characteristics
of CVU treated with HVWM vs standard of care.
Methods: This prospective single-center trial included patients with
duplex ultrasound conﬁrmed CVU of at least 12-weeks’ duration that had
failed standard care for at least 6 weeks. Patients with active infections
and ischemia (ankle-brachial index <0.8) were excluded. All patients
received standard multilayer compression bandages and local wound care.
Half the patients also received HVWM applications once every 1 to 2 weeks
for 6 weeks. The primary outcome was the proportion of completely healed
wounds (ulcer healing rate). The secondary outcome was the percentage
change in total ulcer surface area during 6 weeks of follow-up.
Results: All 20 patients enrolled were men; mean age was 68 years.
Duplex ultrasound imaging conﬁrmed superﬁcial, or a mixture of superﬁcial>Eastern Vascular Society
Fig. A, Venous ulcer. B, Healed ulcer after applications of human
viable wound matrix (HVWM). C, Healing rates versus compression alone.
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mean of 10.8 months in these patients (Fig, A and B). The ulcer-healing
rate was 60% in the HVWM group (n ¼ 10 limbs) and 20% in the stan-
dard-care group (n ¼ 10 limbs; P < .05). The percentage change in total
surface area after 6 weeks of treatment was 83.2% in the HVWM group
vs 24.7% in the standard-care group (P < .05; Fig, C).
Conclusions: Patients with chronic venous ulcers treated with a prod-
uct that delivers viable mesenchymal stem cells directly to the wound
achieved superior healing rates over standard treatment alone. Larger trials
will be required to conﬁrm these early ﬁndings.
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Mortality Can Be Reduced in Infrainguinal Reconstruction Even With
an Aggressive Open Surgical Approach in the Endovascular Era: The
Beneﬁts of a Standardized Approach and Regionalization of Carey
R. Clement Darling III, Philip S. K. Paty, Sean P. Roddy, Benjamin B.
Chang, Paul B. Kreienberg, Kathleen J. Ozsvath, John B. Taggert, Yaron
Sternbach. Albany Medical College, Albany, NYyNew England Society for Vascular SurgeryObjectives: Distal revascularization has undergone a transformation
during the last 25 years. With the improvement of endovascular technology
and antiplatelet therapy, many have adopted an aggressive endovascular
approach using open reconstruction sparingly, partially because of the
perception of signiﬁcant mortality and morbidity after open procedures.
During the past 5 years, our group has used a balanced standardized
approach to distal revascularization, using primary open reconstruction for
patients with signiﬁcant foot necrosis, deep space infection, and any
adequate venous conduit. We have also developed a comprehensive network
to transfer patients who need complex reconstructions to a tertiary center
for more deﬁnitive care.
Methods: Data were prospectively collected from our vascular regis-
try. Patient demographics, type of procedure, mortality, morbidity, and
limb salvage were recorded. We compared results from 2003 to 2008
(group A) with results from 2008 to 2013 (group B). In 2008, we adopted
a standardized approach in our practice for patients presenting with signif-
icant peripheral vascular disease.
Results: From 2003 to 2008, our group performed 2996 infrain-
guinal reconstructions (2309 open bypass and 687 endovascular).
Operative mortality was 2.84% (3.33% open, 1.16% endovascular).
From 2008 to 2013, 4321 infrainguinal reconstructions were per-
formed (2314 open, 2007 endovascular). Total mortality was 1.25%
(1.94% open, 0.9% endovascular). The differences were statistically sig-
niﬁcant. Limb salvage and major complications were similar and not
signiﬁcant.
Conclusions: Standardization of indications and procedures and
appropriate transfer of complex patients to a dedicated center can reduce
mortality of patients undergoing infrainguinal reconstruction while main-
taining quality outcomes.
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Objectives: This study was designed to examine the long-term out-
comes after endovascular aneurysm repair (EVAR).
Methods: All clinical preoperative, operative, postoperative, and
follow-up data of patients undergoing EVAR between 2008 and 2012
were collected prospectively and examined retrospectively. Presence of
endoleak, need for secondary intervention, and survival were analyzed.
Results: A total of 464 patients underwent EVAR with approved de-
vices. The average age was 78.9 6 8.0 years, and 379 (82%) were men. Ur-
gent or emergency EVAR was performed in 32 patients (7.1%). The 30-day
mortality was 2.4%. During an average follow-up of 45.4 6 19.1 months,
the relative survival was 62% by Kaplan-Meier analysis. Endoleak developed
in 83 patients (18%): 13 type I (3%), 67 type II (14%), and 2 type III (0.4%).
The average time to detection of endoleak was 17 months (range, 3-54
months), and 27 endoleaks (33%) were detected after the ﬁrst postoperative
computed tomography scan. Spontaneous resolution of type II endoleak
was observed in 40 patients (59%). A total of 57 secondary interventions
were required in 44 patients (9.5%). Indications for reintervention included
type I endoleak in 15 (26%), type II endoleak with sac expansion >5 mm in
30 (53%), limb kinking or thrombosis in 10 (18%), and renal artery stenosis
in 2 (3.5%). Initial secondary intervention was successful in 35 patients
(80%). Freedom from reintervention was 95% at 1 year and 90% at 5 years,
and the average time to reintervention was 20.56 8.3 months. Preoperative
sac size, current systemic anticoagulation, and history of smoking, diabetes,
or hyperlipidemia did not predict development of endoleak or need for
reintervention.
Conclusions: Despite overall favorable results in this contemporary
series, the rate of required secondary intervention at an average of nearly
2 years postprocedure is unchanged from previous reports. The range of
time to initial presentation of endoleak underscores the continued need
for long-term clinical and radiologic surveillance.
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